

## Supplementary material

**Supplementary Table 1:** Proportional of patients that achieved undetectable HBV DNA levels (<10 IU/mL).

	<b>LAM Treated (n=166)</b>	<b>TDF Treated (n=299)</b>	<b>P Value</b>
<b>F1-BL</b>	67/166 (40.4%)	138/299 (46.2%)	0.228
<b>F2-F1</b>	17/99 (17.2%)	32/161 (19.9%)	0.588
<b>F3-F2</b>	2/82 (2.4%)	14/129 (10.9%)	0.031*
<b>F4-F3</b>	2/80 (2.5%)	7/115 (6.1%)	0.313
<b>F5-F4</b>	0/78 (0.0%)	3/108 (2.8%)	0.266

BL – baseline; Chi square test or Fisher’s exact test was performed to determine the statistical significance between LAM and TDF treatment groups.

**Supplementary Table 2:** Proportional of patients with ALT normalization (<35 IU/mL for males and <25 IU/mL for females).

	<b>LAM Treated (n=166)</b>	<b>TDF Treated (n=299)</b>	<b>P Value</b>
<b>F1-BL</b>	62/166 (37.3%)	116/299 (38.8%)	0.759
<b>F2-F1</b>	7/104 (6.7%)	27/183 (14.8%)	0.043*
<b>F3-F2</b>	3/97 (3.1%)	16/156 (10.3%)	0.048*
<b>F4-F3</b>	2/94 (2.1%)	6/140 (4.3%)	0.480
<b>F5-F4</b>	0/92 (0.0%)	2/134 (1.5%)	0.515

BL – baseline; Chi square test or Fisher’s exact test was performed to determine the statistical significance between LAM and TDF treatment groups.